Signaling by the tumor-suppressor protein p53 antagonizes CRISPR–Cas9 gene editing of human pluripotent stem cells and immortalized human retinal pigment epithelial cells.
This is a preview of subscription content, log in via an institution to check access.
Marina Spence/Springer Nature
References
Urnov, F. D. CRISPR J. 1, 34–46 (2018).
Doudna, J. A. & Charpentier, E. Science 346, 1258096–1258096 (2014).
Hockemeyer, D. & Jaenisch, R. Cell Stem Cell 18, 573–586 (2016).
Ihry, R. J. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0050-6 (2018).
Haapaniemi, E. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0049-z (2018).
Meyers, R. M. et al. Nat. Genet. 49, 1779–1784 (2017).
Tebas, P. et al. N. Engl. J. Med. 370, 901–910 (2014).
Qasim, W. et al. Sci. Transl. Med. 9, eaaj2013 (2017).
Urnov, F. D. Curr. Opin. Genet. Dev. 52, 48–56 (2018).
Schwartz, S. D. et al. Lancet 385, 509–516 (2015).
da Cruz, L. et al. Nat. Biotechnol. 36, 328–337 (2018).
Dunbar, C. E. et al. Science 359, eaan4672 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Urnov, F.D. A path to efficient gene editing. Nat Med 24, 899–900 (2018). https://doi.org/10.1038/s41591-018-0110-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-018-0110-y
- Springer Nature America, Inc.
This article is cited by
-
Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
Journal of Hematology & Oncology (2019)